Category: GLP-1s

While weight loss drugs have been touted as a game-changer for the nation’s obesity epidemic, many Americans who would benefit most from the medications often lack access, experts told the Los Angeles Times in an April 15 report.

Researchers are expanding horizons for the diseases and disorders that GLP-1s such as Ozempic, Mounjaro and Wegovy could treat.

Physicians and researchers say more data is needed on pregnancy outcomes in patients taking GLP-1s as a growing number of women turn to the class of weight loss medications in hopes of reducing their risk of pregnancy complications or increasing their …

After achieving promising outcomes for patients with sleep apnea, Eli Lilly said April 17 it plans to seek a wider FDA approval for Mounjaro and Zepbound. 

Available evidence does not suggest a link between the use of GLP-1 receptor agonists, including Ozempic and Wegovy, and suicidal thoughts or actions, according to a review from drug regulators in Europe. 

Surprise pregnancies may be an unexpected side effect experienced by women who use Ozempic or other GLP-1 medications, The Washington Post reported April 5.

A small study has found lixisenatide, a GLP-1 made by Sanofi, may slow the progression of Parkinson’s disease, according to findings published April 3 in The New England Journal of Medicine. 

After patients and clinicians reported weeklong back orders of Zepbound, Eli Lilly’s new weight loss drug, the FDA confirmed shortages of two Zepbound solutions. 

Six months after Costco announced its entrance into the healthcare industry with $29 virtual primary care visits, the big box retailer is launching a specialized weight loss program exclusively for its members. 

Physicians estimate up to 15% of people who try GLP-1s — the popular class of anti-obesity medications that includes drugs that include Ozempic and Wegovy — lose less than 5% of their body weight, The Wall Street Journal reported April 1.